MedTrace Logo

Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

NCT05504915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2023-11-02

No results posted yet for this study

Summary

Inflammatory bowel disease consists of ulcerative colitis (UC) or Crohn's disease (CD). The main aim of this study is to describe real-world data on vedolizumab serum concentration and treatment outcomes in cohort of patients treated at the Department of Gastroenterology and Hepatology of University Hospital Center Osijek. Study will be recruiting patients who switched from intravenous to subcutaneous vedolizumab according to routine clinical practice.

Conditions

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Colitis, Ulcerative

Sponsors & Collaborators

  • Josip Juraj Strossmayer University of Osijek

    collaborator OTHER

  • Osijek University Hospital

    lead OTHER

Principal Investigators

  • Vlasta Oršić Frič, MD · University Hospital Center Osijek

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05504915 on ClinicalTrials.gov